Targeted dosing to treat pediatric inflammatory bowel disease is challenging because dosing guidelines are based on data gathered from adult subjects of clinical trials. Patients’ families and health care organizations also incur high costs and must try to balance potential benefits against risks of ongoing monitoring.
Patient safety is a medical ethics issue that must be addressed through health care teams’ open communication as well as through time-outs and checklists.
Does a patient’s request not to have a diagnosis included in her health record undermine a clinician’s capacity to provide clinically and ethically appropriate treatment?